News stories about Catalent (NYSE:CTLT) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalent earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.0728496158994 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
Several research analysts have weighed in on the stock. Goldman Sachs Group assumed coverage on shares of Catalent in a research note on Wednesday, January 24th. They set a “buy” rating and a $50.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. ValuEngine cut shares of Catalent from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, First Analysis assumed coverage on shares of Catalent in a research report on Friday, January 5th. They set an “equal weight” rating on the stock. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $45.00.
Shares of Catalent (NYSE:CTLT) traded down $0.46 during trading hours on Friday, reaching $46.60. 1,360,000 shares of the company traded hands, compared to its average volume of 719,012. The firm has a market capitalization of $6,190.00, a PE ratio of 54.19, a price-to-earnings-growth ratio of 2.94 and a beta of 1.47. Catalent has a 52-week low of $27.48 and a 52-week high of $47.87. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The company had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. During the same quarter last year, the company earned $0.16 earnings per share. The firm’s revenue for the quarter was up 23.0% on a year-over-year basis. research analysts predict that Catalent will post 1.48 EPS for the current fiscal year.
In other Catalent news, Director Uwe Roehrhoff bought 7,500 shares of the stock in a transaction dated Tuesday, November 21st. The shares were acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Catalent (CTLT) Earns News Impact Score of 0.06” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/04/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-catalent-ctlt-stock-price.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.